Trinity College

Trinity College Digital Repository
Faculty Scholarship
2010

Purines and the Anti-Epileptic Actions of Ketogenic Diets
Susan A. Masino
Trinity College, susan.masino@trincoll.edu

Masahito Kawamura Jr.
David N. Ruskin
Trinity College, david.ruskin@trincoll.edu

Jeremy Gawryluk
University of North Dakota

Xuesong Chen
University of North Dakota

See next page for additional authors

Follow this and additional works at: https://digitalrepository.trincoll.edu/facpub
Part of the Medicine and Health Sciences Commons

Authors
Susan A. Masino, Masahito Kawamura Jr., David N. Ruskin, Jeremy Gawryluk, Xuesong Chen, and
Jonathan D. Geiger

This article is available at Trinity College Digital Repository: https://digitalrepository.trincoll.edu/facpub/25

58

The Open Neuroscience Journal, 2010, 4, 58-63

Open Access

Purines and the Anti-Epileptic Actions of Ketogenic Diets
Susan A. Masino*,1, Masahito Kawamura, Jr.1,2, David N. Ruskin1, Jeremy Gawryluk3,
Xuesong Chen3 and Jonathan D. Geiger3
1

Department of Psychology/Neuroscience Program, Trinity College, Hartford, Connecticut, 06106, USA, 2Department
of Pharmacology, Jikei University School of Medicine, Minato-ku, Tokyo, Japan, and 3Department of Pharmacology,
Physiology and Therapeutics, University of North Dakota School of Medicine and Health Sciences, Grand Forks, North
Dakota 58201, USA
Abstract: Ketogenic diets are high in fat and low in carbohydrates and represent a well-established and effective treatment alternative to anti-epileptic drugs. Ketogenic diets are used for the management of a variety of difficult-to-treat or intractable seizure disorders, especially pediatric refractory epilepsy. However, it has been shown that this dietary therapy
can reduce seizures in people of all ages, and ketogenic diets are being applied to other prevalent medical conditions such
as diabetes. Although used effectively to treat epilepsy for nearly 90 years, the mechanism(s) by which ketogenic diets
work to reduce seizures remain ill-understood. One mechanism receiving increased attention is based on findings that ketogenic diets increase the brain energy molecule ATP, and may also increase the levels and actions of the related endogenous inhibitory neuromodulator adenosine. ATP and adenosine have both been identified as important modulators of seizures; seizures increase the actions of these purines, these purines regulate epileptic activity in brain, adenosine receptor
antagonists are pro-convulsant, and adenosinergic mechanisms have been implicated previously in the actions of approved
anti-epileptic therapeutics. Here we will review recent literature and describe findings that shed light on mechanistic relationships between ketogenic diets and the purines ATP and adenosine. These emerging mechanisms hold great promise
for the effective therapeutic management of epileptic seizures and other neurological conditions.
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INTRODUCTION
Epilepsy is a prevalent brain disorder characterized by a
predisposition to generate seizures due to excessive or asynchronous neuronal activity in brain [1]. The incidence of
epilepsy is particularly high in young children ( 5 years
old), in young adults especially those engaged in combat,
and in those over the age of 65 [2, 3]. As a neurological disorder, epilepsy is poorly classified as it has multiple known
and unknown genetic and environmental causes, manifestations, seizure types, and identifiable syndromes; an onset of
epilepsy associated with head trauma, central nervous system
infections, and tumors may occur at any age [3]. The incidence and prevalence of epilepsy have been increasing because of combat-associated head injuries and an aging population, and this trend is predicted to continue [4, 5]. Thus,
new therapeutic strategies are needed, and effective interventions could benefit a broad and growing population.
Antiepileptic drugs (AEDs) are used typically and widely
for the treatment of epilepsy. The aim of AED treatment is to
control seizures while minimizing adverse side-effects; unfortunately AEDs are effective for only 60–70% of epileptic
individuals, and undesirable side-effects are not uncommon
[6-8]. In ancient times, epilepsy was treated through the dietary intervention of starvation, which forces a switch from
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glucose-based to ketone-based metabolism. This simple but
extreme treatment led to the hypothesis and its clinical confirmation that maintaining ketone-based metabolism by limiting carbohydrates, while still ingesting adequate calories,
could control seizures [9]. Currently a major alternative and
non-pharmacological treatment for epilepsy is adhering to a
high-fat, low-carbohydrate ketogenic diet (KD), and over
many years its efficacy has been confirmed in retrospective,
prospective, and multi-center studies [10-13]. Since its inception, KD has been employed to maintain ketosis and control epileptic seizures primarily in children who do not respond well to AEDs [14, 15].
KETOGENIC DIETS AND EPILEPSY: APPLICATIONS, BENEFITS AND LIMITATIONS
The KD requires strict compliance to maintain anticonvulsant effects. It limits the consumption of carbohydrates
persistently and sufficiently such that the carbohydrate content does not provide enough glucose to serve as an available
energy source. Without adequate glucose, the brain is forced
metabolically to switch from mostly glycolytic pathways to
ketolytic mechanisms whereby ketones are produced (mainly
in the liver) and used as the main fuel to generate ATP for
cellular metabolism.
The KD ratio prescribed clinically is a specific ratio of
fat to protein plus carbohydrate. A typical KD contains the
ratio of 4:1 (fat: protein + carbohydrates). Approximately
90% of dietary calories are derived from fat whereas < 5%
comes from carbohydrates [16, 17]. Proteins are added to the
diet to meet requirements depending on the individual’s age
2010 Bentham Open
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and size. In some treatment protocols, fluids and calories are
restricted - total caloric intake is targeted to 75% of the recommendation for the individual’s age; however there is no
evidence that forced caloric restriction or fluid restriction is
necessary for the clinical benefit to be observed [18].
As noted, an analogous switch to ketone-based sources of
cellular energy occurs during fasting/starvation. Without
imposing unhealthy fasting/starvation approaches, adherence
to a KD can provide adequate calories and energy while protecting against generation of epileptic seizures. The diet reduces seizure frequency by greater than 90% for one-third of
children on the diet and by greater than 50% for an additional one-third of children [19, 20]. It appears that a KD is
more or less as effective in controlling seizure activity in
adults as it is in treating children with epilepsy, but there
have been comparatively few studies on adults [21, 22]. One
reason why a KD is more commonly applied in and perceived as successful in pediatric epilepsy is that it is easier to
initiate, control food intake and maintain this strict diet in
children. Most pediatric patients that respond well to the KD
are weaned from the diet after two years because the anticonvulsant effect achieved is often permanent [23, 24].
Although the KD is highly effective, it does have its
shortcomings; main criticisms include it being a diet that is
restrictive and unpalatable. In addition, it can cause constipation, kidney stones, and, depending on the saturated fat composition of the diet, cardiovascular complications [25-28]. A
low-carbohydrate diet with a healthier fat composition might
reduce complications [29]. More research is clearly needed
in this area to determine more accurately side effects and
long terms consequences.
To date, the key mechanisms underlying the success of a
KD in reducing seizures are unclear [30, 31]. Proposed
mechanisms include increased GABA, increased mitochondrial gene expression, direct effects of ketones on neurons,
pH changes, and altered ion channels - particularly K+ channels. This knowledge gap has limited the use of KDs for epilepsy and potentially other disorders, as well as stymied efforts to develop drugs that could take advantage of the anticonvulsant mechanisms mobilized by a KD [32]. Despite its
efficacy, KD treatment has inherent drawbacks and limitations and a better mechanistic understanding of its actions
could lead to better diet-based approaches including those
with fewer restrictions and complications. Importantly, an
understanding of underlying mechanisms should result in
new directions for basic and clinical research [33].
Here we focus on the relationship between adhering to a
KD and increased brain levels of ATP and adenosine as a
new insight into epilepsy treatment. The purines ATP and
adenosine link metabolism to neuronal activity [34], and cell
bioenergetics may be a key regulator of seizure activity [35,
36]. Importantly, adenosine is an endogenous anticonvulsant
[37-39] which is effective in numerous seizure models, including acute and chronic electroconvulsive and pharmacological paradigms [40-44], and is also effective in pharmacoresistant kainate-induced seizures [45-47].
Adenosine acting at the adenosine A1 receptor (A1R) subtype could be the final key mechanism by which adhering to
a KD prevents seizures [48, 49]. Although more research is
needed, to date there are a few seizure models where both
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adenosine and a KD have been shown to be effective, including electrical kindling of the amygdala in rats [42-44, 50],
acute bicuculline injection [41, 51, 52], pentylenetetrazol
kindling in mice [53-55], and the epileptogenic phase after
kainate treatment [45-47, 56, 57]. Overall, a purine-targeting
metabolic strategy - ultimately increasing the actions of the
anticonvulsant molecule adenosine - has great potential to
treat a wide variety of epileptic seizures.
EPILEPSY AND ENERGY METABOLISM
During seizures neurons undergo prolonged depolarization that leads to large fluxes of ions across plasma membranes. As a result there is intracellular accumulation of sodium and calcium ions, and an increased requirement to expend large amounts of energy (mostly ATP) to re-establish
the interior milieu. ATP is necessary to maintain resting
membrane potentials, and depletion of intracellular ATP in
an effort to export accumulated ions can lead to bioenergetic
crisis and/or redox catastrophe. Sodium-potassium-ATPase
is largely responsible for maintaining these ionic gradients
[58]; under basal conditions it has been estimated that
ATPase consumes 25-40% of the brain’s energy [59], and
after seizure activity ATPase likely consumes an even
greater percentage of brain energy to restore the resting
membrane potential. Decreased levels of ATP can reduce the
cell’s energy charge and its ability to maintain homeostasis
and normal neuronal function and signaling, and, during an
acute energy demand such as a seizure, the need for ATP
can very readily and rapidly supersede supply. Thus, adequate intracellular ATP is central to controlling cellular energy, seizure generation, and neuronal membrane polarity.
Compared to the large and constant levels of ATP inside
the cell, extracellular ATP is relatively insignificant and
transient. A net dephosphorylation of ATP to ADP, AMP
and adenosine occurs extremely rapidly (the t of ATP in the
extracellular space is about 200 ms [60]). Together, ATP and
its core molecule adenosine are intricately involved in maintaining cellular energy levels and in controlling neuronal
excitability via cell-surface receptors. Intracellular adenosine
is especially important because it is a very sensitive measure
of the balance between cellular energy supplies and energy
demand. Its actions to reduce neuronal activity and energy
demand and re-establish equity between supply and demand
via feedback on cell-surface receptors is a concept central to
adenosine being considered a retaliatory metabolite [61].
Extracellular adenosine is a powerful endogenous anticonvulsant, with great potential for treating all types of epileptic
seizures. Traditionally, adenosine has been recognized as the
brain’s own anticonvulsant molecule and a powerful endogenous neuromodulator: tonic levels are present throughout the extracellular space, it is released from cells during
seizures, ischemia, and hypoxia [62-64], its actions can also
be increased by stimuli such as changes in temperature and
pH [65-70], and it may be more sensitive to these changes
during conditions of increased excitability [71].
Adenosine is released during seizures, and adenosine
through its activation of high-affinity A1Rs contributes to
termination of seizures by reducing neuronal excitability [45,
72-74]. Activation of A1Rs pre- and postsynaptically decreases excitatory neurotransmitter release [75] and hyperpolarizes postsynaptic membrane potentials by promoting po-
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tassium conductance [76]. The brain in general and the seizure-prone hippocampus in particular contain high levels of
A1Rs. There is abundant evidence that the powerful anticonvulsant role of endogenous adenosine occurs through this
receptor subtype [77-80]. For example the ictal EEG events
of bicuculline-injected rats were suppressed by focal application of adenosine [78] and A1R agonists suppress even
pharmacoresistant epilepsy of kainate injected mice [45].
Conversely, antagonists of A1Rs are pro-convulsant [81].
Thus, adenosine is similar to the KD in that both are effective at reducing seizures that are refractory to other treatments. Unfortunately, drug-based strategies that directly target adenosine A1Rs generally face vexing pharmacological
obstacles including peripheral side effects such as reduced
heart rate and blood pressure [82]. More recently, localized
adenosine based-therapies show significant promise but are
necessarily invasive and best suited to well-localized, focal
seizures [80, 83].
Extracellular ATP is a major source of extracellular
adenosine [84, 85], and, as noted, is metabolized rapidly to
adenosine [60]; these enzymatic reactions are catalyzed by a
variety of ecto-ATPases and 5’-nucleotidases [60]. Thus,
increased levels of either purine in seizure-prone brain areas
containing A1 Rs could help to either prevent or to terminate
seizures. At this time it is neither well-understood how a KD
differentially affects purinergic mechanisms and metabolism
in various cell types in the central nervous system, nor has it
been determined what roles different cell types might play in
a KD’s anticonvulsant benefits. Nevertheless, it has been
established that ATP and adenosine in the central nervous
system can originate from neurons themselves as well as
from other cell types, most notably from astrocytes. Astrocytes are abundant, and particularly complex in humans [86,
87], and purines released from astrocytes influence synaptic
transmission. Astrocytes release ATP through hemichannels
as well as from neurosecretory vesicles; extracellular adenosine derived from astrocytic ATP influences neuronal excitability, plasticity, and sleep [88-90]. However, astrocyte involvement in the relationship between purines and epilepsy
is complicated by findings that astrogliosis occurs in epilepsy and brain injury, astrocytes transport adenosine into
the cell interior, adenosine kinase very actively catalyzes the
phosphorylation of adenosine to AMP within astrocytes, and
increased levels of adenosine kinase decreases the extracellular levels and actions (including anticonvulsant actions) of
adenosine [91].
PURINES AND THE KETOGENIC DIET
Many hypotheses have been advanced and tested in ongoing attempts to determine mechanisms responsible for the
antiepileptic effects of a KD. Acidosis, dehydration and ketosis were the first mechanisms to be considered when the
KD was first introduced as a metabolic strategy which could
mimic fasting-induced seizure protection [15]. None of these
initial mechanisms appeared sufficient to explain clinical
observations, and subsequently, investigators attributed the
protective actions of a KD to alterations in levels of neurotransmitters (including GABA, norepinephrine and glutamate), glucose restriction, activation of ATP-sensitive K +
channels, circulating factors including polyunsaturated fatty
acids and their downstream effectors, decreased neuronal
excitability, transformations of cerebral energy metabolism
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and increased purines [15, 30, 48]. Identifying critical anticonvulsant mechanisms underlying the success of KD therapy remains a topic of intense research, and changes in gene
expression, altered energy metabolism, and changes in the
levels and actions of purines are very strong candidates [48,
49, 92-94].
For over 30 years it has been recognized that KD can
lead to increased levels of ATP in brain [92] and it also increases the ratio of phosphocreatine to ATP [95]. More recently we used methods able to provide precise and accurate
measures of brain energy metabolites in brain and reported
that rats fed a calorie-restricted KD for three weeks had increased ratios of phosphocreatine to creatine in hippocampus
[94]; such increases suggest that alternative sources of high
energy phosphate are available and might thereby protect
against ATP utilization and depletion. Subsequently, we
showed that KD increased levels of ATP in brains of KD-fed
1
animals.
Some clinical reports suggest that a KD can offer seizure
protection promptly [96, 97], and some research shows that
acute ketone treatment can be directly anticonvulsant [98].
At least two reports show that ketones or an in vitro analogue of ketogenic metabolism increases hyperpolarization
via postsynaptic ATP-sensitive K+ channels [99, 100]. However, many reports note that a KD can take several days or
weeks before becoming maximally effective [eg. 101]. Accordingly, it was hypothesized that this delay was due to
alterations in gene expression generally and more specifically due to alterations in genes involved in the control of
energy metabolism [94]. Using gene microarray technology,
normal 37-41 day old rats placed on a KD for 21 days were
found to have upregulated genes for oxidative phosphorylation. In agreement with this, mitochondrial biogenesis was
increased, and, as noted above, brain levels of phosphocreatine relative to creatine were increased [94]. Thus,
improved brain bioenergetic status might play an important
role in the anti-seizure effects of KD.
Measured increases in cell bioenergetics in conjunction
with the gene array data suggest strongly that brain energy
metabolism in general and purines in particular might be
mechanisms central to the therapeutic effects of the KD. Increasingly, recent research and proposed hypotheses about
the KD suggest that higher levels of both ATP and adenosine
underlie some of the anticonvulsant success as well as
emerging applications for a KD and analogous ketogenic
metabolic strategies [33, 48, 49, 100]. Augmenting extracellular adenosine offers both pre- and postsynaptic inhibitory
mechanisms as well as established clinical potential beyond
epilepsy including brain injury, pain and sleep disorders [33,
88]. Furthermore, understanding the mechanisms underlying
the success of KD for epilepsy would be a major breakthrough, as this metabolism-based therapy can alleviate seizures even in cases of intractable epilepsy.
Clinical observations that a KD can be effective in intractable epilepsy suggest that although the spectrum of mechanisms underlying the success of KD therapy could overlap,
they must be distinct from those targeted primarily by AEDs.
1
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Research in animal models is very clear that adenosine is a
powerful global and local seizure-suppressor, and an adenosine or A1R deficiency alone is sufficient to trigger seizure
activity [47, 102]. To date, a variety of adenosinergic
mechanisms have been implicated in the actions of AEDs
including AEDs interacting with A1Rs and increasing their
anti-epileptic effectiveness, and AEDs binding to A1Rs directly [103-105]. When considering all of the intra- and extracellular regulatory mechanisms for controlling the levels
and actions of purines in brain, and the respective contributions of neurons and astrocytes, the greatest net benefit of the
anticonvulsant effects of purines would be achieved by 1)
maintaining overall cell energy levels, 2) at least maintaining
(if not increasing) cellular levels of ATP, and 3) increasing
levels of extracellular adenosine, either directly or as a consequence of increased extracellular ATP and its dephosphorylation to adenosine.
In addition to evidence that a KD in vivo may change
ATP and adenosine, increases in these purines have been
implicated in cellular consequences of ketogenic metabolism
both in vitro and in vivo. For example, moderate hypoglycemia or glycolytic inhibition can both increase adenosine
[106-108] and offer anticonvulsant benefits [109, 110]. Recent electrophysiological evidence shows that sufficient or
high intracellular ATP and lowered extracellular glucose
mobilizes an autocrine inhibition via A1Rs [100]. Diverse
findings that a KD or ketogenic metabolic strategies work
through purines, and particularly through adenosine, does
not negate or eliminate other metabolic changes precipitated
by this metabolic switch. Rather, these findings may help
simultaneously pinpoint specific and critical mechanisms
and identify a new strategy for adenosine regulation, opening
new avenues for the treatment of seizure disorders and a
broad array of other diseases.
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SUMMARY
Traditionally, the KD is used mainly in children. While it
has limitations, KD therapy may be more effective in the
management of childhood seizures than currently available
AEDs [111], and can offer permanent benefits [112]. The
KD might also slow the progression of this disorder and thus
be antiepileptogenic [56, 113]. Certainly more research is
needed in this area. Unfortunately, until the mechanism(s) by
which the KD provides protection are better delineated, this
knowledge gap makes is difficult to fashion an even better
and more widely accessible therapeutic approach. Nevertheless, with respect to the relationship among KDs and purines,
a better insight into how this metabolic switch influences
purines could yield new approaches to purine-based therapies which have shown potential for treating a diverse array
of acute and chronic conditions.
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